



Universiteit
Leiden
The Netherlands

TCRs as precision tools against B-cell and plasma cell malignancies

Meeuwsen, M.H.

Citation

Meeuwsen, M. H. (2024, October 1). *TCRs as precision tools against B-cell and plasma cell malignancies*. Retrieved from <https://hdl.handle.net/1887/4093497>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4093497>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER

5

Cutting Edge: Unconventional CD8+ T-cell recognition of a naturally occurring HLA-A*02:01- restricted 20mer epitope

Miranda H. Meeuwse^{*}

Anne K. Wouters^{*}

Renate S. Hagedoorn^{*}

Michel G.D. Kester^{*}

Dennis F.G. Remst^{*}

Dirk M. van der Steen^{*}

Arnoud de Ru[†]

Peter A. van Veelen[†]

Jamie Rossjohn^{‡,§,¶}

Stephanie Gras^{‡,§,||}

J.H. Frederik Falkenburg^{*}

Mirjam H.M. Heemskerk^{*}

^{*}Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands. [†]Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands. [‡]Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia. [§]Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, VIC, Australia. [¶]Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. ^{||}Present address: Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC, Australia.

The Journal of Immunology 2022
Vol. 208, Issue 8, Pages 1851-1856

ABSTRACT

Unconventional HLA class I-restricted CD8+ T-cell epitopes, longer than 10 amino acids, have been implicated to play a role in human immunity against viruses and cancer. T-cell recognition of long peptides, centrally bulging from the HLA cleft, has previously been described. Alternatively, long peptides can contain a linear HLA-bound core peptide, with a N or C-terminal peptide 'tail' extending from the HLA peptide binding groove. The role of such a peptide 'tail' in CD8+ T-cell recognition remains unclear. Here, we identified a 20mer peptide (FLP) derived from the IL27RA gene restricted to HLA-A*02:01, for which we solved the crystal structure and demonstrated a long C-terminal 'tail' extension. FLP specific T-cell clones demonstrated various recognition modes, some T cells recognized the FLP core peptide, while for other T cells the peptide tail was essential for recognition. These results demonstrate a crucial role for a C-terminal peptide tail in immunogenicity.

INTRODUCTION

HLA class I (HLA-I) presented peptide epitopes are key components of CD8+ T-cell responses to pathogens and in cancer through recognition of neo-epitopes. HLA-I complexes present peptides derived from cellular proteins on the cell surface. HLA-I peptide complexes are formed in the endoplasmic reticulum (ER), where HLA-I single chains and β 2-microglobulin (β 2m) assemble and incorporate peptides present in the ER. The ER peptide reservoir is mainly composed of peptides derived from cytosolic protein degradation by the proteasome, which are subsequently transported into the ER through peptide transporter TAP, which preferentially binds peptides of 8-16 amino acids in length (1). Besides this classical pathway, peptides can end up in the ER, independent of TAP transport, through alternative peptide processing pathways (2). For example, the C-terminal tail of type-II transmembrane proteins, which is located inside the ER lumen, can be cleaved by signal peptide peptidase releasing C-terminal peptides into the ER (3). After localization into the ER, either through TAP or via alternative pathways, peptides are available for binding to HLA. Once binding to HLA has occurred, peptide-HLA (pHLA) complexes are transported to the cell surface where recognition by T cells can take place. The HLA-I peptide binding groove contains six pockets (A-F), of which the B and F pocket typically bind the N and C terminally located anchor residues of peptides respectively (4). Conventional peptides bind the B pocket through the amino acid residue at position 2 (p2) and the F pocket with the last residue p Ω . The HLA-I peptide binding groove is flanked by closed A and F pockets, generally limiting the length of binding peptides and resulting in preferential presentation of canonical peptides of 8-11 amino acids in length. Longer peptides can fit in HLA through binding of both anchor residues while bulging out of the groove in the center of the peptide or adapting a zig-zag conformation (5). Additionally, the C-terminal part of unconventional long peptides can protrude through the closed F pocket, resulting in a conventionally bound core peptide with a solvent exposed C-terminal 'tail' hanging from the groove (6, 7). Moreover, N-terminal peptide tails extending from the A pocket have been described (8). Mass spectrometry-based studies revealed that unconventional long peptides compose around 5-10% of the HLA-I peptide repertoire (9-12). In addition to their relatively high abundance, T-cell recognition of multiple long peptides has been described to play a role in viral as well as anti-tumor T-cell immunity (13-16).

Previously, a large set of TCR-pHLA crystal structures was reviewed and demonstrated the general consensus of TCR docking on canonical pHLA complexes (17, 18). In the reported TCR-pHLA-I complexes the TCRs were oriented in a 37-90° angle over the peptide binding groove, with the variable domain of the TCR α chain generally located over the α 2 helix and the TCR β chain over the α 1 of the HLA molecule. The three loops located at the membrane distal end of both TCR chains contain CDR1, CDR2 and CDR3.

CDR1 and CDR2 (encoded by the germline variable (V) gene) interact primarily with the HLA molecule, while the hypervariable CDR3 domain binds to the peptide and HLA molecule.

Longer peptides usually bulge centrally from the peptide binding cleft (5). Bulged peptides were described to be recognized through varying TCR docking mechanisms. Rigid peptide bulges maintain their original conformation upon TCR ligation while more motile bulges can be flattened upon TCR interaction (16, 19-21). T cells recognizing bulged long peptides were shown to engage with the core of the peptide bulging out of the HLA groove. In contrast, it is unknown how *N* or *C-terminal* peptide tails extending from HLA cleft, impact T-cell recognition. To gain insight into the role of the peptide tail in the interaction with CD8⁺ T cells, we investigated HLA binding of a naturally occurring 20mer peptide FLPTPEELGLLGPPRPQVLA (referred to as FLP) derived from the IL27RA protein presented in HLA-A*02:01 (HLA-A2). We solved the crystal structure of the HLA-A2-FLP complex and revealed that only the first 11 amino acids of the peptide bound in the HLA-A2 binding groove (FLPTPEELGLL), while a proline-rich solvent exposed C-terminal tail of 9 residues (GPPRPQVLA) extended from the F pocket of the HLA-A2 molecule. T cells recognizing the FLP peptide revealed that part of the C-terminal ‘tail’ can be critical for T-cell recognition, providing new insight in the diversity of T cells recognizing unconventional long peptides in HLA-I.

RESULTS AND DISCUSSION

Identification of an HLA-A2 binding 20mer peptide

In a previous study, we mapped the HLA-I peptidome of LCLs by peptide elution followed by mass spectrometry (9, 22). HLA-I peptides were eluted using W6/32 antibody followed by selection of peptides containing anchor residues for HLA-I. This study revealed that HLA-I presented peptide longer than 11 amino acids occur more frequently than previously anticipated. Here, we investigated HLA binding and T-cell recognition of 20mer peptide FLPTPEELGLLGPPRPQVLA (FLP) identified by Hassan *et al.*, which originated from the C-terminal end of the interleukin-27 receptor α (IL27RA) protein. The FLP peptide was eluted from HLA-A2+ LCL-HHC but not from HLA-A2+ LCL-JYW (**Figure 1**). The FLP peptide contains multiple potential anchor residues that suggest binding to HLA-A2. For example, the leucine at position 2 could act as the p2 anchor residue for binding to HLA-A2. Alternatively, in case of an unconventional N-terminal peptide tail extending from the HLA groove, leucine at p8, p10 or p11 could act as the p2 anchor residue. Additionally, the C-terminal p Ω anchor residue could be the leucine at p10, p11 or p19 as well as the valine at p18. Stable binding of FLP to HLA-A2 was confirmed by successful refolding and crystallization of the HLA-A2-FLP complex.




Figure 1. Identification of IL27RA derived length variants of FLP peptide from HLA-A2+ LCLs. HLA class I presented peptides were eluted from 40x10⁹ HLA-A2+ LCLs and measured by mass spectrometry. Length variants of FLP peptides derived from the IL27RA protein were identified. Shown are frequencies of detection, determined by number of detected sample scans, of FLP length variant from LCL-HHC (in grey) and LCL-JYW (in black).

Crystal structure of HLA-A2-FLP revealed the presence of a long C-terminal ‘tail’

To investigate how the FLP peptide was presented by the HLA-A2 molecule, we solved the crystal structure of the HLA-A2-FLP complex at 1.7 Å resolution (**Table S1**). The crystal structure contains two molecules in the asymmetric unit. The superposition of the two pHLA complexes revealed that they both adopted the same conformation, with a root mean square of 0.23 Å for the antigen binding cleft and 0.34 Å for the peptide (**Figure 2A**). Therefore, the structural analysis was performed with one of the complexes. The HLA-A2-FLP structure revealed that amino acids at p1-p11 bind in the HLA-A2 peptide binding groove in the same manner as conventional HLA class-I presented peptides, with p11-L as the pΩ anchor residue (**Figure 2B**). Amino acids p12-p20 extend from the F-pocket and form a solvent exposed C-terminal ‘tail’. Part of the peptide tail (p12-p17) was clearly defined in the electron density (**Figure S1A-B**), while the electron density was weak for C-terminal residues (p18-p20) indicating high flexibility of this part. The proline-rich nature of the p12-p17 extended region presumably added rigidity to this section of the peptide, thereby enabling it to be readily visualized (19).




Figure 2. Crystal structure of the HLA-A2-FLP complex. **A)** Superposition of the two HLA-A2-FLP complexes present in the asymmetric unit represented as cartoon in green and orange. **B)** Structure of the FLP-20mer peptide (cartoon and stick) in the cleft of HLA-A2 (white cartoon). The first 11 residues of the FLP-20mer peptide colored in green are bound to the antigen binding cleft, while the C-terminal tail (purple) is coming out of the cleft.

Identification of FLP peptide specific CD8+ T cells revealed immunogenicity

To assess the immunogenicity of FLP peptide, T cells were isolated from HLA-A2 negative healthy donors to circumvent immunogenic tolerance for this non-mutated self-peptide (23, 24). Using HLA-A2-FLP-tetramers we successfully isolated CD8+ T-cell clones (**Figure 3A**). These T-cell clones demonstrated functional recognition of FLP peptide upon peptide titration using HLA-A2 Td Raji cells (**Figure 3B**). Unloaded *IL27RA* negative Raji cells were not recognized, showing FLP peptide specificity (**Figure 3B, Figure S1C**).

Recognition of endogenously processed and presented FLP peptide was observed by T cells stimulated with *IL27RA* expressing T2 cells (**Figure 3C, Figure S1C**), indicating that the identified T-cell clones were potent enough to recognize target cells naturally expressing the *IL27RA* gene. Additionally, recognition of T2 cells was enhanced by retroviral overexpression of the *IL27RA* gene (**Figure 3C**). Similarly, Td of *IL27RA* into Raji cells induced recognition, validating the requirement for *IL27RA* expression for target cell recognition. Recognition of TAP deficient T2 cells by FLP specific T-cell clones suggests that FLP peptide, which is located at the C-terminal end of the *IL27RA* protein, is processed and presented independent of TAP transport through an alternative pathway remaining to be identified. This observation is in accordance with the overrepresentation of C-terminal peptides in the ligandome of TAP deficient cells (25).




Figure 3. Reactivity of FLP specific T-cell clones. **A)** T cell clone 1A5.19, 1B4.25 and 1G8.26 stained with IL27RA FLP pHLA-tetramer-PE (grey red or blue) or control CMV NLV HLA-A2 tetramer (white) gated on live cells. **B-E)** IFN- γ production after overnight co-culture. Values represent mean of technical duplicates, data are representative examples of three experiments. **B)** T-cell clones co-cultured with Raji cells Td with HLA-A2 loaded with decreasing FLP peptide concentrations. **C)** T-cell clones co-cultured with Raji cells Td with HLA-A2 (Raji +A2), Raji + A2 additionally Td with the IL27RA gene (+IL27RA), HLA-A2+ wild type (WT) T2 cells, T2 cells Td with the IL27RA gene (+IL27RA), HLA-A2+ WT LCLs from donor HHC, HLA-A2+ WT LCLs from donor JYW and medium (TCM) only. **D)** Raji +A2 loaded with 100nM c-terminal length variants of FLP peptide. **E)** Raji +A2 loaded with 100nM Ala scan of FLP 15mer peptide.

Finally, LCLs from donors HHC and JYW were co-cultured with the T-cell clones, despite similar natural *IL27RA* expression levels (**Figure S1C**), LCLs from donor HHC were recognized while LCLs from donor JYW were not recognized (**Figure 3C**). This corresponded with the difference in abundance of FLP length variants in peptide elution data of the two LCLs (**Figure 1**), which demonstrated that FLP length variants, including the 20mer peptide, were abundantly present on LCL-HHC cells, whereas no 20mer peptide, and only one length variant could be detected in the peptide elution data of LCL-JYW (**Figure 1**). In total, length variants of FLP were identified 21 times from LCL-HHC while only 2 times from LCL-JYW. The substantial difference in detection of FLP length variants indicated differential involvement of the pathway underlying presentation of FLP peptides in LCL-HHC and JYW.

Solvent exposed C-terminal ‘tail’ of FLP peptide plays a role in T-cell recognition

To investigate if the solvent exposed ‘tail’ of FLP peptide plays a role in T-cell recognition, C-terminal length variants of FLP were loaded on HLA-A2 Td Raji cells. Recognition by T-cell clone 1A5.19 was located in the core between p1-p11 of FLP peptide, as recognition was not influenced by length variations of the tail (p12-p20) (**Figure 3D**). Recognition was lost upon stimulation with FLP-10mer peptide, demonstrating the requirement for the p11-L anchor residue to be present that would likely conserve the same core structure as the 20mer peptide. T-cell clone 1B4.25 demonstrated a comparable recognition pattern but additionally recognized FLP-10mer peptide at a reduced level (**Figure 3D**), indicating that p10-L could act as an alternative, but less efficient anchor residue. Finally, T-cell clone 1G8.26 recognized FLP 20-14mer peptides to the same extent as FLP-20mer peptide, but recognition was abrogated upon stimulation with FLP-13mer or shorter peptides (**Figure 3D**). Therefore, the proline at p14 played an essential role in recognition by this T-cell clone, demonstrating that the proximal part of the C-terminal peptide ‘tail’ was involved in T-cell recognition. For all T-cell clones no differences were observed between recognition of FLP-20mer and FLP-15mer indicating that p15-p20 did not influence T-cell recognition. To confirm that amino acids in the proximal part of the ‘tail’ are important for recognition by T-cell clone 1G8.26, an Ala scan of FLP-15mer was generated and loaded onto HLA-A2 Td Raji cells. For T-cell clones 1A5.19 and 1B4.25 Ala substitutions between p12 and p15 did not influence recognition of the FLP peptide, whereas recognition by T-cell clone 1G8.26 was abrogated when p13 and p14 were replaced by Ala, confirming the previously observed role of the proximal part of the peptide tail for recognition by this clone (**Figure 3E**). In addition, Ala substitutions between p1 and p11 demonstrated that all three clones recognized the core region of the peptide but exhibited differential recognition patterns of the FLP pHLA-A2 complex. Thus, T-cell clone 1G8.26 recognized the core as well as the tail region of the FLP peptide, while clones 1A5.19 and 1B4.25 recognized the core peptide alone. The combined recognition of the core region as well as proximal part of the tail by clone 1G8.26 suggested that upon TCR binding, the

peptide tail is oriented away from the peptide binding groove rather than being folded back over the linear peptide core, thereby allowing simultaneous TCR contact with the core as well as the proximal part of the peptide tail.

Remesh *et al* previously reported that longer peptides extend at the C terminus by opening the F-pocket with a charged amino acid not more than 3 residues after the pΩ anchor (7). In our study, the crystal structure of the HLA-A2-FLP complex does not reveal opening of the F-pocket, and in addition the first charged amino acid at p15 was found to be irrelevant for recognition (**Figure 3D,E**). Demonstrating that a C-terminal peptide tail can extend from the HLA cleft without opening of the F-pocket by a charged amino acid.

To conclude, these results demonstrated immunogenicity of a 20mer peptide composed of a conventional core peptide and a C-terminal peptide tail coming out the F-pocket presented in HLA-A2. One of three identified T-cell clones required the peptide tail to allow peptide recognition, highlighting that the proximal part of the C-terminal peptide tail can be a crucial component of such an unconventional T-cell epitope. These results contribute to the knowledge about the dynamic range in functional T-cell epitopes that exist beyond canonical peptides. The variable recognition patterns observed between T-cell clones would indicate that the TCRs bind FLP through different docking modes, and further study will be required to gain a detailed understanding of the interaction between TCRs and this unconventional peptide.

MATERIALS AND METHODS

Peptide identification

HLA-I peptidomes of HLA-A2+ EBV transformed B lymphoblastic cell lines (LCLs) LCL-HHC and LCL-JYW were previously determined by peptide elution and mass spectrometry analysis (22). Peptide length variation was assessed for peptides containing anchor residues for binding to expressed HLA-I alleles (9). In this study pHLA monomers containing 20-mer peptide FLPTPEELGLLGPPRPQVLA (FLP) derived from the Interleukin-27 receptor subunit alpha (IL27RA) in HLA-A2 were folded and used to generate pHLA-tetramers as previously described by Hassan *et al* (9). Peptides were synthesized by standard Fmoc chemistry and dissolved in DMSO.

Protein expression, purification, crystallization and structure determination

DNA plasmids encoding HLA-A2 α-chain (1-275) and human β2m were transformed separately into a BL21 strain of *E. coli*. Recombinant proteins were expressed insoluble as inclusion bodies, extracted and purified. Soluble pHLA complex was produced by

refolding 30 mg HLA-A2 α -chain, 5 mg β 2m and 5 mg FLP peptide in a 0.5L buffer of 3M Urea, 0.5 M L-Arginine, 0.1 M Tris-HCl pH 8.0, 2.5 mM EDTA pH 8.0, 5 mM glutathione (reduced), 1.25 mM glutathione (oxidised). The mixture was stirred at 4°C for 3h and dialysed against 10L of 10 mM Tris-HCl pH 8.0 three times over a 24h period (26). Soluble pHLA was purified using anion exchange chromatography using a HiTrapQ column. The HLA-A2-FLP complex was crystallised using vapor diffusion method with a 1:1 ratio of protein:mother liquor. The protein was 5 mg/ml in 0.1M Tris-HCl pH8 and 0.15M NaCl, and the mother liquor was composed of a mixture of 0.12M Monosaccharides (D-Glucose; D-Mannose; D-Galactose; L-Fucose; D-Xylose; N-Acetyl-D-Glucosamine), 0.1M of Na-HEPES and MOPS buffer at pH 7.5, 20% w/v Glycerol and 10% w/v PEG 4000. The crystals were flash frozen in liquid nitrogen and data were collected on the MX1 beamline at the Australian Synchrotron, part of ANSTO, Australia (27). The data were processed using XDS (28) and the structure was determined by molecular replacement using the PHASER program (29) from the CCP4 suite (30) with a model of HLA-A2 without peptide (derived from PDB ID: 3GSO DOI: [10.4049/jimmunol.0900556](https://doi.org/10.4049/jimmunol.0900556)). Manual model building was conducted using COOT (31) followed by refinement with BUSTER (32). The final model has been validated and deposited using the wwPDB OneDep System with accession code: 7T5M. The final refinement statistics are summarised in supplemental Table 1. All molecular graphics representations were created using PyMOL.

T cell isolation

PBMCs were isolated from buffy coats obtained from HLA-A2 negative healthy donors after written informed consent according to the Declaration of Helsinki. pHLA-tetramer+ CD8+ T cells were enriched, single-cell sorted and clonally expanded as previously described (9). FLP-A2 specificity was determined by pHLA-tetramer stain.

Target cell generation

T2 and Raji cells were transduced (Td) with IL27RA in a MP71-IRES-NGFR vector. Td cells were purified for transgene expression by MACS before use in experiments. Raji cells were additionally Td with HLA-A2 in a PLZRS-markerless vector and purified.

T-cell assay

T-cell stimulation assays were performed by overnight incubation of 5,000 T cells with 30,000 target cells in 384 well plates. For peptide recognition target cells were loaded with 100nM peptide or decreasing concentrations starting at 1 μ M in peptide titration experiments. IFN- γ production was measured by ELISA. C-terminal length variants of FLP peptide were generated. Purity of all length variants was confirmed by HPLC and mass spectrometry. FLP 15-mer peptide was used for alanine (Ala) scanning, all amino acids were separately substituted by an Ala.

RT-qPCR

IL27RA expression was measured by quantitative RT-PCR (qRT-PCR) as previously described (24). Gene expression was calculated relative to the average expression of housekeeping genes: *GUSB*, *PSMB4* and *VPS29*.

REFERENCES

1. van Endert PM, Tampé R, Meyer TH, Tisch R, Bach JF, McDevitt HO. A sequential model for peptide binding and transport by the transporters associated with antigen processing. *Immunity*. 1994;1(6):491-500.
2. Oliveira CC, van Hall T. Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome. *Front Immunol*. 2015;6:298.
3. Oliveira CC, Querido B, Sluijter M, de Groot AF, van der Zee R, Rabelink MJ, et al. New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. *J Immunol*. 2013;191(8):4020-8.
4. Nguyen AT, Szeto C, Gras S. The pockets guide to HLA class I molecules. *Biochem Soc Trans*. 2021;49(5):2319-31.
5. Josephs TM, Grant EJ, Gras S. Molecular challenges imposed by MHC-I restricted long epitopes on T cell immunity. *Biol Chem*. 2017;398(9):1027-36.
6. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. *Nature*. 1994;371(6498):626-9.
7. Remesh SG, Andreatta M, Ying G, Kaever T, Nielsen M, McMurtry C, et al. Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT. *J Biol Chem*. 2017;292(13):5262-70.
8. Pymm P, Illing PT, Ramarathnam SH, O'Connor GM, Hughes VA, Hitchen C, et al. MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape. *Nature Structural & Molecular Biology*. 2017;24(4):387-94.
9. Hassan C, Chabrol E, Jahn L, Kester MG, de Ru AH, Drijfhout JW, et al. Naturally processed non-canonical HLA-A*02:01 presented peptides. *The Journal of biological chemistry*. 2015;290(5):2593-603.
10. Hickman HD, Luis AD, Buchli R, Few SR, Sathiamurthy M, VanGundy RS, et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. *Journal of immunology (Baltimore, Md : 1950)*. 2004;172(5):2944-52.
11. Mommen GP, Frese CK, Meiring HD, van Gaans-van den Brink J, de Jong AP, van Els CA, et al. Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (ETHcD). *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(12):4507-12.
12. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? *Trends Immunol*. 2006;27(1):11-6.
13. Pudney VA, Leese AM, Rickinson AB, Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. *J Exp Med*. 2005;201(3):349-60.
14. Tynan FE, Borg NA, Miles JJ, Beddoe T, El-Hassen D, Silins SL, et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. *The Journal of biological chemistry*. 2005;280(25):23900-9.
15. Probst-Keppler M, Hecht HJ, Herrmann H, Janke V, Ocklenburg F, Klempnauer J, et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501. *Journal of immunology (Baltimore, Md : 1950)*. 2004;173(9):5610-6.
16. Chan KF, Gully BS, Gras S, Beringer DX, Kjer-Nielsen L, Cebon J, et al. Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. *Nat Commun*. 2018;9(1):1026.
17. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor recognition of antigen-presenting molecules. *Annu Rev Immunol*. 2015;33:169-200.
18. La Gruta NL, Gras S, Daley SR, Thomas PG, Rossjohn J. Understanding the drivers of MHC restriction of T cell receptors. *Nat Rev Immunol*. 2018;18(7):467-78.
19. Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. *Nat Immunol*. 2005;6(11):1114-22.
20. Tynan FE, Reid HH, Kjer-Nielsen L, Miles JJ, Wilce MC, Kostenko L, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. *Nat Immunol*. 2007;8(3):268-76.
21. Liu YC, Miles JJ, Neller MA, Gostick E, Price DA, Purcell AW, et al. Highly divergent T-cell receptor binding modes underlie specific recognition of a bulged viral peptide bound to a human leukocyte antigen class I molecule. *The Journal of biological chemistry*. 2013;288(22):15442-54.

22. Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, et al. The human leukocyte antigen-presented ligandome of B lymphocytes. *Mol Cell Proteomics*. 2013;12(7):1829-43.
23. Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. *Clin Cancer Res*. 2011;17(17):5615-25.
24. Jahn L, van der Steen DM, Hagedoorn RS, Hombrink P, Kester MG, Schoonakker MP, et al. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. *Oncotarget*. 2016;7(47):77021-37.
25. Martín-Galiano AJ, López D. Computational characterization of the peptidome in transporter associated with antigen processing (TAP)-deficient cells. *PloS one*. 2019;14(1):e0210583.
26. Chatzileontiadou DSM, Szeto C, Jayasinghe D, Gras S. Protein purification and crystallization of HLA-A*02:01 in complex with SARS-CoV-2 peptides. *STAR Protoc*. 2021;2(3):100635.
27. Aragão D, Aishima J, Cherukuvada H, Clarken R, Clift M, Cowieson NP, et al. MX2: a high-flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian Synchrotron. *J Synchrotron Radiat*. 2018;25(Pt 3):885-91.
28. Kabsch W. XDS. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 2):125-32.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr*. 2007;40(Pt 4):658-74.
30. The CCP4 suite: programs for protein crystallography. *Acta crystallographica Section D, Biological crystallography*. 1994;50(Pt 5):760-3.
31. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 4):486-501.
32. Bricogne G, BE, Brandl M., Flensburg C., Keller P., Paciorek W.,, Roversi P SA, Smart O.S., Vonrhein C., Womack T.O. Buster version 2.10. Cambridge, United Kingdom: Global Phasing Ltd. 2011.

SUPPLEMENTARY MATERIAL




Figure S1. Crystal structures of FLP peptide and gene expression of the *IL27RA* gene. A-B) Electron density maps contoured at 3σ colored in green for the Fo-Fc map (A), and contoured at 1σ colored in blue for the 2Fo-Fc map (B). The peptide and HLA are colored as in Fig 1B. **C)** *IL27RA* gene expression in LCL-JYW, LCL-HHC, T2 and Raji cells measured by qPCR, depicted relative to housekeeping genes (HKG).

Table S1. Data collection and refinement statistics

Data Collection Statistics	HLA-A2-FLP
Space group	P22 ₁ 2 ₁
Cell Dimensions (a,b,c) (Å)	70.18, 99.90, 135.46
Resolution (Å)	48.74 – 1.67 (0.70 – 1.67)
Total number of observations	823981 (34622)
Nb of unique observation	111273 (5154)
Multiplicity	7.4 (6.7)
Data completeness (%)	997 (94.3)
I/s _i	13.2 (2.4)
R _{pim} ^a (%)	4.1 (35.1)
CC _{1/2} (%)	99.8 (72.0)
Refinement Statistics	
R _{factor} ^b (%)	18.7
R _{free} ^b (%)	20.8
rmsd from ideality	
Bond lengths (Å)	0.008
Bond angles (°)	0.98
Ramachandran plot (%)	
Favoured	99.03
Allowed	0.97
Disallowed	0

^a $R_{p.i.m} = \sum_{hkl} [1/(N-1)]^{1/2} \sum_i |I_{hkl,i} - \langle I_{hkl} \rangle| / \sum_{hkl} \langle I_{hkl} \rangle$. ^b $R_{factor} = \sum_{hkl} ||F_o| - |F_c|| / \sum_{hkl} |F_o|$ for all data except $\approx 5\%$ which were used for R_{free} calculation. Values in parentheses are for the highest resolution-shell.